Pinz Capital Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Pinz Capital Management’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$20K	–	440
2021 Q2	$20K	Buy	+1,000	New	+$17K	0.01%	368

Other funds holding AMAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Pinz Capital Management's AMAM Position: Q3 2021 in Review

Pinz Capital Management sold out of Ambrx Biopharma Inc (AMAM) in Q3 2021, closing a stake of 1,000 shares — an estimated $20K sold.

Pinz Capital Management first reported a position in AMAM in Q2 2021 and held it in 1 quarter. The position peaked at $20K in Q2 2021. 15 funds tracked by Wall St. Rank hold AMAM as of Q3 2021.

Pinz Capital Management reported no remaining Ambrx Biopharma Inc position as of Q3 2021 after selling out during the quarter.
Pinz Capital Management sold 1,000 Ambrx Biopharma Inc shares in Q3 2021, an estimated $20K.
Pinz Capital Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 1 quarter.
Pinz Capital Management's Ambrx Biopharma Inc position peaked at $20K in Q2 2021.
15 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.